(Q24248739)

27 June 2017

1 reference

title

Naltrexone maintenance treatment for opioid dependence (English)

1 reference

27 June 2017

0 references

0 references

U Kirchmayer

1

0 references

author name string

M Davoli

series ordinal

2

1 reference

27 June 2017

A Verster

series ordinal

3

1 reference

27 June 2017

U Kirchmayer

series ordinal

1

1 reference

27 June 2017

language of work or name

English

0 references

publication date

22 April 2003

0 references

1 January 2000

1 reference

Cochrane Database of Systematic Reviews

27 June 2017

2002

0 references

2001

0 references

2000

0 references

published in

1 reference

27 June 2017

CD001333

1 reference

27 June 2017

4

1 reference

Opiate Antagonists and the Modification of Heroin Self-Administration Behavior in Man: An Experimental Study

27 June 2017

2

0 references

cites work

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001333

The treatment of heroin addiction: naltrexone alone and with behavior therapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001333

Naltrexone-induced dysphoria in former opioid addicts

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001333

Narcotic antagonist treatment: clinical experience with naltrexone

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001333

Naltrexone, an antagonist for the treatment of heroin dependence. Effects in man.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001333

Closing the gap between research and practice: an overview of systematic reviews of interventions to promote the implementation of research findings. The Cochrane Effective Practice and Organization of Care Review Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001333

Naltrexone and cyclazocine. A controlled treatment study

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001333

7 January 2021

Methadyl acetate (LAAM) in the treatment of heroin addicts. II. Double-blind comparison of gradual and abrupt detoxification

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001333

7 January 2021

Psychosocial factors in outcome in two opiate addiction treatments.

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001333

7 January 2021

The efficacy of naltrexone in preventing reabuse of heroin after detoxification.

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001333

7 January 2021

Naltrexone treatment of opiate-dependent persons

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001333

7 January 2021

Naltrexone treatment of heroin addiction: efficacy and safety in a double-blind dosage comparison

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001333

7 January 2021

Multiple family therapy and naltrexone in the treatment of opiate dependence

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001333

7 January 2021

Naltrexone treatment of heroin addiction: one-year follow-up.

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001333

7 January 2021

Determination of naltrexone dosage for narcotic agonist blockade in detoxified Asian addicts.

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001333

7 January 2021

The Atwood Hall Health Promotion Program, Federal Medical Center, Lexington, KY. Effects on drug-involved federal offenders

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001333

7 January 2021

Naltrexone pharmacotherapy for opioid dependent federal probationers

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001333

7 January 2021

Follow-up after a six-month maintenance period on naltrexone versus placebo in heroin addicts.

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001333

7 January 2021

Studies of EN-1639A (Naltrexone): A New Narcotic Antagonist

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001333

7 January 2021

Clinical Experience with Naltrexone

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001333

7 January 2021

Experiences with Naltrexone in Buffalo

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001333

7 January 2021

Craving in heroin addicts maintained on the opiate antagonist naltrexone

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001333

7 January 2021

Controlled clinical study of naltrexone side effects comparing first-day doses and maintenance regimens

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001333

7 January 2021

The Double-Blind Crossover Trial Design: How Good Is It for Psychoactive Drugs?

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001333

7 January 2021

Psychosocial adjustment, modality choice, and outcome in naltrexone versus methadone treatment.

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001333

7 January 2021

10.1002/14651858.CD001333

Identifiers

DOI

1 reference

27 June 2017

1 reference